1 / 6

Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort.

swarajnanda
Download Presentation

Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026 Market Research Report Telephone :+1(503)894-6022 Mail at =Sales@researchbeam.com

  2. Report Overview • Epiomic™ Epidemiology Series Forecast Report on Autoimmune HaemolyticAnaemia (AIHA) in 8 Major Markets • Autoimmune haemolyticanaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition. • This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. • Providing a value-added level of insight from the analysis team at, several of the main symptoms and co-morbidities of AIHAs have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

  3. Main symptoms and co-morbidities for AIHA include: • Lymphoproliferative conditions: • CLL • HL • NHL • Myeloproliferative conditions: • Multiple myeloma • Myelofibrosis • MGUS • Autoimmune conditions: • RA • SLE • Polyarteritisnodosa • Infections: • Pneumonia & Tuberculosis • Syphilis • Epstein-Barr • Chronic active hepatitis • Mononucleosis

  4. Reason to buy • This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report. • Able to quantify patient populations in global AIHAs market to target the development of future products, pricing strategies and launch plans. • Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential. • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. • Provide a level of understanding on the impact from specific co-morbid conditions on AIHAs incident population. • Identify sub-populations within AIHA which require treatment. • Gain an understanding of the specific markets that have the largest number of AIHA patients.

  5. Table Of Content • • List of Tables and Figures• Introduction• Cause of the Disease• Risk Factors & Prevention• Diagnosis of the Disease• Variation by Geography/Ethnicity• Disease Prognosis & Clinical Course• Clinical Management of AIHAo Transfusion therapy in AIHA• Key Co-morbid Conditions/Features Associated with the Disease• Methodology for Quantification of Patient Numbers• Top-Line Incidence for AIHA • Subtypes of AIHA patientso Warm AIHA patientso Cold AIHA patientso Mixed-type AIHA patients• Market Forecast for AIHAo 1st Line Treatment Options within Warm & Mixed-type AIHAo 2nd Line Treatment Options within Warm & Mixed-type AIHAo 1st Line Treatment Options within Cold AIHAo 2nd Line Treatment Options within Cold AIHAo Requirement for Blood Transfusions within AIHA• Methodology for Forecast Figures• Abbreviations used in the report • Other Black Swan Analysis Publications• Black Swan Analysis Online Patient-Based Databases• Patient-Based Offering• Online Pricing Data and Platforms• References• Appendix 

  6. Find More Details • http://www.researchbeam.com/epiomic-epidemiology-series-autoimmune-haemolytic-anemia-forecast-in-8-major-2016-2026-market/enquire-about-report Stay With Us: • TELEPHONE: +1 (800) 910-6452 • DIRECT: +1 (503) 894-6022E-MAIL: sales@researchbeam.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States

More Related